Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.
Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...
Reader's Digest Canada on MSN4d
30 Old-Time Home Remedies That Actually WorkHoney to heal a wound. Cherries for gout. Cod-liver oil— blech!—to keep your eyes healthy. Your grandmother and her doctors ...
The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced that the first subject has been dosed in ...
Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...
Natural treatments for lupus are typically used as complementary therapies alongside conventional treatments. Learn more ...
ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis ZORYVE, a next-generation topical phosphodiesterase-4 ...
The novel oral first-in-class anti-inflammatory agent has demonstrated robust efficacy and high safety margins in preclinical studies, and is the first drug candidate to advance to clinical trials ...
Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Enrolling Patients in Second Dosing Cohort Interim Data from Atopic Dermatitis Trial Expected to be Announced December 2024 Registration Phase 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback